SCHEMBL30808259

SCHEMBL30808259

Cc1nc(N)c2scc(C)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 1/20 0.41
PDPK1 O15530 1/20 0.37
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PRKCI P41743 9/20 0.35
PIK3CA P42336 1/20 0.35
NOS1 P29475 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
RXFP1 Q9HBX9 2/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34
KMT2A Q03164 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
TNKS O95271 1/20 0.33
PARP1 P09874 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25637211 1.00 LIMK1 (0.41) LIMK1PDPK1HTTSMN1; SMN2PRKCI
SCHEMBL21880616 0.81 CDK1 (0.35) PDPK1HTTSMN1; SMN2PRKCIPIK3CA
SCHEMBL13780028 0.79 PDPK1 (0.39) PDPK1SMN1; SMN2PRKCIPIK3CANPSR1
SCHEMBL5313472 0.78 PDPK1 (0.38) PDPK1HTTSMN1; SMN2PRKCIPIK3CA
SCHEMBL12094370 0.76 PDPK1 (0.37) PDPK1SMN1; SMN2PRKCIPIK3CANPSR1
SCHEMBL5579149 0.76 PDPK1 (0.37) PDPK1SMN1; SMN2PRKCIPIK3CANPSR1
SCHEMBL19933209 0.73 PRKCI (0.40) PDPK1HTTSMN1; SMN2PRKCINPSR1
SCHEMBL25171225 0.72 PDPK1 (0.37) PDPK1SMN1; SMN2PRKCIPIK3CANOS1
SCHEMBL20777126 0.72 PIK3CA (0.38) PDPK1HTTSMN1; SMN2PRKCIPIK3CA
SCHEMBL1868539 0.72 NPC1 (0.50) LIMK1PDPK1MAPTNPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113039182-B Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment 伊文蒂瓦公司 2024-02-20 CN disclosed